Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/lamivudine-containing HAART regimen

Antiviral Therapy

Volumn 11, Issue 6, 2006, Pages 701-705

  Descamps, Diane ^a   Ait Khaled, Mounir ^b   Craig, Charles ^b   Delarue, Séverine ^a   Damond, Florence ^a   Collin, Gilles ^a   Brun Vézinet, Françoise ^a  

^a BICHAT HOSPITAL   (France)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR PHOSPHATE; EFAVIRENZ; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CASE REPORT; DRUG TREATMENT FAILURE; GENE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; K65R GENE; MOLECULAR CLONING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 33749322743     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10:975-981.
2. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998; 177:1521-1532.
3. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996; 276:118-125.
4. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety or tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
5. Miller V, Ait-Khaled M, Stone C, et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14:163-171.
6. Miller V, Sturmer M, Staszewski S, et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.
7. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
8. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr 2004; 37 Suppl 1:S36-43.
9. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′- dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38:275-281.
10. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997; 41:1094-1098.
11. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
12. Masquelier B, Tamalet C, Montes B, et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 2004; 9:315-323.
13. Staszewski S, Dauer B, Stuermer M, et al. Predictors of loss of virologic response to tenofovir DF (TDF) therapy in HIV-1+ patients. The XV International AIDS Conference. 11-16 July 2004. Bangkok, Thailand. Abstract WePeB5713
14. Bae AS, Waters JM, Margot NA, Borroto-Esoda K, Miller M. Pre-existing L74V is a risk factor for virological non-response and development of K65R in patients taking tenofovir DF (TDF). Antivir Ther 2004; 9:S174
15. Moffatt A, Gerondelis, P, Stone C, et al. Population and clonal sequence analyses in HIV-1+ subjects treated with abacavir (ABC)/lamivudine (3TC)/efavirenz (EFV). 4th European AIDS Conference, Dublin. 17-20 November, 2005. Abstract H-1067.
16. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94:45-54.
17. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75:6410-6417.
18. Delaunay C, Brun-Vezinet F, Landman R, et al. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005; 79:9572-9578.
19. Craig C, Stone C, Bonny T, et al. Analysis of virologic failure (VF) in a clinical trial of abacavir (ABC)once daily (OAD) versus twice daily (BID) with lamivudine (3TC) and efavirenz (EFV) (Zodiac Study: CNA30021). 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA. February 8-11, 2004. Abstract 551.
20. Irlbeck D, Rouse E, Castillo S, et al. Treatment-emergent mutations for previously naive HIV-infected adults failing ZDV+3TC+EFV and ABC+3TC+EFV (CNA30024). 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA. February 8-11, 2004. Abtract 661.
21. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 35:22-32.
22. Schürmann D, Gathe J, Sanne I, Wood R, on behalf of the SOLO Study Team. Efficacy and safety of GW433908/ritonavir once-daily in theraoy naive subjects, 48 weeks results: the SOLO Study. 6th International Congress on Drug Therapy and HIV Infection 2002, November 17-21, Glasgow, UK. Abstract PL14.4
23. Mellors J, Palmer S, Nissley D, et al. Low frequency non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI mutations. XII International HIV Drug Resistance Workshop: Basic principles and Clinical Implications. 10-14 June, 2003, Los Cabos, Mexico. Abstract 134.